Last Updated on August 13, 2020 by The Health Master
India’s supply of antiviral drug remdesivir and generic equivalents is stabilising after shortages of the vital COVID-19 medicine at hospitals, said Kedar Upadhye, Global Chief Financial Officer, Cipla.
Cipla’s launch of remdesivir in late June, along with subsequent launches by others, has helped ease supply bottlenecks in India, said Upadhye.
India, one of the world’s biggest producer of generic drugs, recommends remdesivir for moderate to severe COVID-19. Doctors also use other drugs, including favipiravir, another antiviral approved for the disease.
Also read: Plasma Therapy becoming success: SDC FDA Haryana
Cipla, which is also free to export the drug, supplies it in South Africa and plans to expand access to “several sub-Saharan African countries”.
Cipla declined to comment on the number of vials of remdesivir it had shipped so far but said it had started making the drug at a plant in Goa in western India to ramp up production.
The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.
